LG Chem will invest 2 trillion won ($1.6 billion) in its biopharmaceuticals business by the end of 2027, aiming to become a major player in the U.S. anticancer market.
LG Chem's cancer immunotherapy candidate, CUE-102, won approval to start Phase 1 clinical trials from the U.S. Food and Drug Administration (FDA).
Korea JoongAng Daily Sitemap